



Lifecycle Assessment of Pharmaceuticals in Irish Surface Waters

Dylan O'Flynn¹, Jenny Lawler², Fiona Regan¹, Blánaid White¹

¹DCU Water Institute, School of Chemical Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland.

²DCU Water Institute, School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.



@EMPIRE_DCU



1

Introduction:

At each stage of a pharmaceutical lifecycle, there is a significant risk of environmental exposure. For this reason, it is imperative to implement both source directed and end of pipe control measures. This will mitigate any potential hazards to the environment or to humans. The ever-increasing use and availability of pharmaceuticals in the last decade have led to the contamination of surface water ecosystems with ng/L to µg/L concentrations. The environmental fate and toxicological implications of many pharmaceuticals and their residues are not fully understood. Additionally, the stability and biological activity of these "micro-pollutants" can lead to chronic environmental exposure causing behavioural and health-related effects. This research investigates pharmaceuticals chosen from the updated surface water "Watch List" (Decision (EU) 2018/840), followed by pharmaceuticals which are commonly found in European surface water and pharmaceuticals which have a low removal efficiency in wastewater treatment plants.¹ This project aims to create a comprehensive prioritisation framework and a risk-based assessment by calculating their risk quotient for each of the chosen pharmaceuticals.

2


Life cycle of pharmaceuticals



3


Pharmaceuticals commonly found in surface water

Each of these chosen pharmaceuticals have been identified as Contaminants of Emerging Concern (CECs).² However, it is not just a single pharmaceutical in the environment, it is a chemical cocktail of many different types and their associated metabolites. This cocktail can lead to an unknown toxicity within the environment and to humans.



4

Factors influencing environmental concentrations and risk assessment



72% of 398 people questioned in Cork and Galway had said they have improperly disposed of medicine in the past.⁴



Climate change! Droughts and floods can drastically alter the dilution of pharmaceuticals in surface water. This can lead to pollution events where the toxic effects of pharmaceuticals are heightened.⁵

Environmental Risk assessment (ERA) for human medicine

Phase 1 • Screening pharmaceuticals for their physicochemical properties and their predicted environmental concentration.

If risks are found → **Phase II A** • Examining the fate and effect of pharmaceuticals in the environment

If risks are found → **Phase II B** • Refining risk assessment and further testing

ERAs are only conducted on pharmaceuticals licenced after 2006.⁶

Acknowledgements

References:

- G. McEneff, W. Schmidt and B. Quinn, Pharmaceuticals in the Aquatic Environment: A Short Summary of Current Knowledge and the Potential Impacts on Aquatic Biota and Humans.
- NORMAN, LIST OF EMERGING SUBSTANCES, https://www.norman-network.com/sites/default/files/files/Emerging_substances_list_Feb_16/NORMAN%20list_2016_FINAL.XLSX
- Umweltbundesamt Database - Pharmaceuticals in the environment.
- A. Vellingaa, S. Cormicana, J. Driscolla, M. Fureya, M. O'Sullivan and M. Cormican, Public practice regarding disposal of unused medicines in Ireland.
- OECD, Pharmaceutical Residues in Freshwater, 2019.
- S. Mudgal, A. De Toni, S. Lockwood, K. Salés, T. Backhaus and B. Halling Sorensen, Study on the environmental risks of medicinal products, 2013, 310.